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Chemokines and their receptors are involved in tumourigenicity and clinicopathological significance of chemokines receptor
expression in pancreatic adenocarcinoma (PA) is not fully understood. This study was conducted to determine patients’ outcome
according to the expressions of CXCR4, CXCR7 and HIF-1a after resection of PA. Immunohistochemistry for CXCR4, CXCR7 and
HIF-1a expressions as well as cell proliferative index (Ki-67) was conducted in 71 resected (R0) PA and their 48 related lymph nodes
(LN) using tissue microarray. CXCR4 and CXCR7 expressions were positively correlated to HIF-1a suggesting a potential role of
HIF-1a in CXCR4 and CXCR7 transcription activation. Patients with CXCR4
high tumour expression had shorter OS than those with
low expression (median survival: 9.7 vs 43.2 months, P¼0.0006), a higher risk of LN metastases and liver recurrence. In multivariate
analysis, high CXCR4 expression, LN metastases and poorly differentiated tumour are independent negative prognosis factors.
In a combining analysis, patients with CXCR4
low/CXCR7
low tumour had a significantly shorter DFS and OS than patients with
a CXCR7
high/CXCR4
high tumour. CXCR4 in resected PA may represent a valuable prognostic factor as well as an attractive target
for therapeutic purpose.
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Pancreatic adenocarcinoma (PA) is characterised by early
locoregional spread and distant metastasis. As a result, most of
the patients are unresectable at the time of diagnosis. Without
treatment, life expectancy of such patients is only 3–6 months
(Burris et al, 1997; Jemal et al, 2007). Despite curative surgery the
5-year overall survival (OS) is around 20%. New strategies and
therapies are urgently needed whereas we also need to identify new
prognostic and predictive biomarkers. A lot of different mecha-
nisms, mediators and pathways have been investigated trying to
explain the PA aggressive phenotype (Furukawa et al, 2006).
Chemokines and their receptors are implicated in the development
of different types of cancers (Mu ¨ller et al, 2001; Schimanski et al,
2005; Nakamura et al, 2006; Yasumoto et al, 2006). In breast and
gastric adenocarcinoma, tumour growth, angiogenesis as well as
the homing of tumour cells to the sentinel lymph nodes and distant
predilection sites are mediated by chemokines and their receptors
(Mu ¨ller et al, 2001; Schimanski et al, 2005; Nakamura et al,
2006; Yasumoto et al, 2006). Chemokines act through specific
7-transmembrane receptors coupled to G proteins (GPCR). They
are present on almost all cell types but were initially identified on
leucocytes, where they are known to play a major role in the
inflammatory process (Proudfoot, 2002).
Stromal-derived factor-1a (SDF-1a or CXCL12) is a broadly
expressed CXC chemokine which serves as a potent chemo-
attractant for mature and immature haematopoietic cells. High
levels of CXCL12 are produced in lymph nodes, liver, lung, bone
marrow or brain. They are common sites of pancreatic metastases
suggesting that this chemokine accounts for the homing of
pancreatic cancer cells to specific organs. The predominant
CXCL12 receptor is the CX chemokine receptor 4 (CXCR4), a
protein frequently overexpressed on the surface of human tumour
cells of epithelial origin (Scotton et al, 2002; Cunha et al, 2003;
Hartmann et al, 2005; Kaifi et al, 2005; Kim et al, 2005; Schimanski
et al, 2005). Most pancreatic cancer cell lines also express CXCR4.
In CXCR4-positive PA cell lines, CXCL12 not only enhances
chemotaxis, transendothelial migration and matrigel invasion, but
also stimulates cell proliferation and protect them from serum
deprivation-induced apoptosis (Koshiba et al, 2000; Marchesi et al,
2004; Saur et al, 2005).
CXCL12 can bind another chemokine receptor, such as CXCR7,
which is present on the surface of many different malignant
cell types (Burns et al, 2006), on tumour-associated blood vessels,
but not on normal vasculature (Miao et al, 2007). CXCR7
promoted the survival of tumour cells by preventing apoptosis,
increased adhesion properties and dissemination, but did not
mediate chemotaxis towards CXCL12 (Burns et al, 2006). CXCR7
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sinduces proliferation of lung, prostatic and breast cancer cell lines
(Burns et al, 2006; Miao et al, 2007; Wang et al, 2008) and tumour
growth enhancement and dissemination in a breast cancer
xenograft mouse model (Burns et al, 2006; Miao et al, 2007).
Although its role in pancreatic cancer development still needs to
be determined, CXCR7 has been supposed to play a role in the
pathogenesis of pancreatic cancer.
The hypoxia inducible factor-1 (HIF-1) induces upregulation of
CXCR4 transcription and CXCR4 transcripts stabilisation (Staller
et al, 2003; Li et al, 2004). For this reason, CXCR4 was proposed to
be responsible for enhanced malignancy of tumour cells in hypoxic
areas (Schioppa et al 2003; Staller et al 2003; Schutyser et al, 2007).
In our study, we evaluated CXCR4, CXCR7 and HIF-1a expres-
sions, their relative impact in the outcome of resected PA patients
and whether these three biomarkers are correlated with clinico-
pathological factors.
MATERIALS AND METHODS
Patients and tissues
Patients with primary PA who had undergone curative surgery
were retrospectively reviewed. Seventy-eight specimens of Whipple
resection and partial pancreatectomy during the period of 1998–
2006 for PC were identified and their formalin-fixed paraffin-
embedded (FFPE) tissue blocks were retrieved in our Department
of Pathology. A complete microscopic resection (R0), including
circumferential retroperitoneal margin evaluation, was achieved
for 71 out of the 78 and they constituted our study population.
Tissue microarray construction
Tissue cores were obtained from FFPE and slides of each case have
been reviewed by a pathologist (PD). Based on the haematoxylin–
eosin staining, representative areas of the tumour (tumour bulk
and invasive margin) and the lymph node (LN) metastasis have
been selected. Five tissue cores of 0.6-mm diameter in each of the
three areas mentioned above were placed into a recipient block by
using a precision arraying instrument (Beecher Instruments; Micro
Tissue Arrayer, Silver Springs, MD, USA). We constructed four
TMA blocks containing a total of 950 cores of ductal adenocarci-
noma. Five-micrometer sections were cut from completed array
blocks and transferred to adhesive slides. Slides were protected
against antigen deterioration by paraffin coating before their use.
Sections were stained with haematoxylin and assessed for adequate
tumour representation.
Immunohistochemistry
Immunohistochemical staining of FFPE tumour tissue was
performed using non-biotinylated rabbit polyclonal anti-human
antibodies against CXCR7 (Abcam, Cambridge, UK; dilution
1:100), mouse monoclonal anti-human CXCR4 (R&D Systems
Inc., Minneapolis, MN, USA; dilution 1:200), mouse monoclonal
anti-human HIF-1a (R&D Systems Inc.; dilution 1:20) and mouse
monoclonal anti-human Ki-67 (Dako, Heverlee, Belgium; clone
Mib-1, dilution 1:1000). Antigen retrieval was performed by
microwave pretreatment in 0.01 M citrate buffer for 10min
(CXCR7, Ki-67). Sections were incubated with mouse anti-rabbit
or goat anti-mouse secondary IgG biotinylated secondary antibody
for 30min. Immunoreactivity was visualised by means of avidin–
biotin–peroxydase complex kit reagents (Biogenex, San Ramon,
CA, USA) as the chromogenic substrate. Finally, sections were
weakly counterstained with Mayers haematoxylin, and mounted.
Hodgkin’s lymphoma (CXCR4), kidney (CXCR7), lymph node
(Ki-67) and prostatic adenocarcinoma (HIF-1a) were used as
positive controls. Irrelevant rabbit or mouse IgG antibodies were
applied to negative control.
Immunostaining grading and score
We used the Spot Browser V2e (Alphe ´lys, Plaisir, France) software
controlling a camera connected to a microscope for the
automatical acquisition of each spot. Slides were scanned using
a customised computer-controlled microscope (Olympus BX50
(Olympus, Aartselaar, Belgium) with xy-stage and z controller).
Images of each spot are acquired automatically with a high-
resolution camera (DXC-390; Sony, Londerzeel, Belgium). Spots
were examined independently by two observers (PD and RM)
blinded to both clinical and pathological data. Immunoposivity
was assessed with respect to cellular localisation (membranous,
cytoplasmic or nuclear), intensity and distribution. Proliferative
activity was assessed by scoring the percentage of labelled cells.
Expressions of CXCR7, CXCR4 and HIF-1a were quantified using a
visual grading system based on the extent of staining (percentage
of positive tumour cells graded on scale from 0 to 3: 0, none; 1,
1–30%; 2, 31–60%; 3, 460%) and the intensity of staining (graded
on a scale of 0–3: 0, none; 1, weak staining; 2, moderate staining; 3,
strong staining). The combination of extent (E) and intensity (I) of
staining was obtained by the product of E I called EI varying
from 0 to 9 for each spot. The mean EI score was calculated for
each PA specimen (tumour bulk þ invasive margin) and their
related LN metastasis.
For statistical analysis, EI score of 0–3 were considered low
expression and EI score 43 were considered high expression. This
cut-off value was based on the immunostaining pattern observed
for CXCR4, HIF-1a and CXCR7 expressions (see below). In case
of CXCR4, CXCR7 and HIF-1a expressions, staining intensity was
quite homogeneous within tumour specimens and all epithelial
cells of adenocarcinoma express CXCR4, CXCR7 and HIF-1a.
Therefore, specimens differ essentially in terms of staining
intensity.
Table 1 Baseline patient characteristics (n¼71)
Variable No. of patients (%)
Total 71
Median age (range); years 64.5 (39–81)
Gender
Male 39 (55)
Female 32 (45)
ECOG PS
0 67 (94)
1 4 (6)
Histologic grade
Poorly differentiated 15 (21)
Well, moderately differentiated 56 (79)
Tumour stage
T1-T2 10 (14.1)
T3-T4 61 (85.9)
Lymph node metastasis
Yes 48 (68)
None 23 (32)
Adjuvant treatment
Radiochemotherapy 30 (42)
Gemcitabine monotherapy 12 (17)
Tumour recurrence
Local 11 (15.5)
Distant 33 (46.5)
Local and distant 13 (18.3)
ECOG PS¼Eastern Cooperative Oncology Group performance status.
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sValidation of the microarray cohort
Spots were excluded from the analysis if they were no tumour or
minimal tumour specimen. We decided that at least two valuable
spots per area of interest are required to calculate the mean EI
score per area. Of the 71 patients, 70 (97.2%) were assessable for
each of the tumour areas located in the primary tumour. Of 48
patients with LN metastasis, 37 (70%) were assessable for LN
tumour cells protein expression.
Statistical analysis
The primary outcome variables were OS and DFS. Survival curves
were estimated using the Kaplan–Meier method (Kaplan and
Meier, 1958) and differences among groups were analysed using
the log-rank test. OS was calculated as the period from the day of
surgical resection to death of any cause or until the date of the last
follow-up, at which point data were censored. DFS was defined as
the time between surgical resection until either of progression of
disease, death from any cause and last radiological assessment.
Data on survivors were censored at the last follow-up. We used
non-parametric tests to compare independent groups of numerical
data (Mann–Whitney test) and categorical data (w
2-test and
Fisher’s exact test). The correlations among numerical variables
were assessed by Spearman’s rank correlation analysis. Multi-
variate analyses, with backward variable selection, were conducted
using the Cox’s proportional-hazards regression model (Cox,
1972). Variables at the 0.10 level in univariate analysis were
included in the multivariate model. The level of significance was
defined as Po0.05. All the statistical analyses were carried out
using the Statistical Package for Social Science 11.0 software
(SPSS Inc., Chicago, IL, USA).
RESULTS
Patients ‘characteristics
Seventy-one patients constituted our case series. Characteristics of
the patients are listed in Table 1. There were 39 men and 32 women
Table 2 CXCR4, CXCR7, HIF-1a expressions: EI score per area
Tumour (TB +IM) LN
CXCR4
Median 3.5 4.0
Range 0.4–5.4 0–6
Patients assessable 71 37
Positive (EI score 40) 60 (84.5%) 24 (65.8%)
Low/high 32/39
CXCR7
Median 4.0 2.0
Range 0.3–7.7 0–4
Patients assessable 71 37
Positive (EI score 40) 53 (74.6%) 22 (59.5%)
Low/high 29/42
HIF-1a
Median 3.7 2.6
Range 0.1–8.6 0–9
Patients assessable 71 37
Positive (EI score 40) 48 (67.6%) 19 (51.4%)
Low/high 33/38
HIF-1a¼hypoxia inducible factor-1a;I M ¼invasive margin; LN¼lymph nodes;
TB¼tumour bulk.
Magnification ×100  Magnification ×200  
Magnification ×100
A
C
B
Figure 1 Immunostaining for CXCR7, HIF1-a, CXCR4 in pancreatic adenocarcinoma. Pancreatic adenocarcinoma showing strong cytoplasmic staining
for CXCR7 (A), HIF1-a (B), CXCR4 (C). Adjacent lymphocytes (A) and (C) demonstrate staining and provide a positive control. (A) Magnification  100;
(B) Magnification  200; (C) Magnification  100.
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swith a median age of 64.5 years (range: 39–81 years). All patients
underwent a R0 duodenopancreatectomy and none were treated
with neoadjuvant therapy. Five patients (7.1%) died from surgical
complications within 1.5 months after resection. These patients
were excluded from survival analysis. Adjuvant treatment was
administered in 42 patients (59%) and consisted in a combination
of chemoradiation for 30 of them and gemcitabine monotherapy
for 12. The median OS was 16.4 months (range: 3.2–107.4) and the
median DFS of 10.1 months (range: 1.4–107.4). Of the 71 patients,
49 (69%) relapsed (11 locally, 25 in distant organs, 13 both locally
and in distant organs) and 38 received chemotherapy after disease
relapsing. At the end of the follow-up period, 17 patients (24%)
were free of disease recurrence.
Expression pattern of CXCR4, CXCR7 and HIF-1a in PA
CXCR4 was expressed in 60 out of 71 tumours (84.5%; Table 2). Of
the 71 tissues, 65 had uniformly detectable CXCR4 immunostain-
ing; 6 samples displayed a proportion (o30%) of adenocarcinoma
cells without undetectable CXCR4. CXCR4 staining showed a
predominantly cytoplasmic distribution in the cancer cells.
CXCR7 expression was restricted to the cytoplasm and present
in 53 out of 71 (74.6%) tumours (Table 2). Like CXCR4,
the expression was homogeneous within a determined specimen.
No staining was observed in the normal acinar and ductal cells
of the peritumoural areas. Weak staining for CXCR4 and CXCR7
was observed in a majority of the infiltrating inflammatory
cells. Furthermore, CXCR4 and CXCR7 were highly expressed in
tumoural blood vessels whereas no staining was observed in the
endothelium of blood vessels in normal pancreatic tissue.
HIF-1a was predominantly identified into the cytoplasm of
cancer cells in 48 out of 71 (67.6%) tumours; and 11 out of 71
(15.5%) displayed nuclear staining (Figure 1). Table 2 summarises
CXCR4, CXCR7 and HIF-1a expressions in the tumours and in
their related LN metastasis.
Correlation among CXCR4, CXCR7 and HIF-1a expressions
HIF-1a expression was positively correlated with those of
CXCR4 and CXCR7 among tumour specimens (HIF-1a-CXCR4,
Spearman’s r¼0.55, Po0.0001; HIF-1a-CXCR7, Spearman’s
r¼0.29, P¼0.013).
Correlation among CXCR4, CXCR7, HIF-1a expressions
and clinicopathological factors
LN metastasis (P¼0.005) and liver recurrence (P¼0.016) were
significantly higher in PA showing high CXCR4 expression than in
those with low expression. None of the other parameters   cancer
stage, tumour differentiation, vascular and perinervous embols  
had a significant relationship to CXCR4 expression (Table 3). We
did not found any association among HIF-1a, CXCR7 tumour
expression and the different clinicopathological factors analysed in
this study (data not shown).
Relationship between CXCR4/CXCR7 expression and
proliferative index
The mean proliferative index (PI) for pancreatic tumours was
22.97±10.37%. There was a significant positive linear correlation
between PI and CXCR4 EI score (Spearman’s r¼0.583, Po0.001;
Figure 2A), but not between CXCR7 EI score and PI. Interestingly,
PI was significantly higher in CXCR4
high/CXCR7
high tumours than
in CXCR4
lowCXCR7
low tumours (mean PI: 29.08±12.33 vs
18.06±5.01, P¼0.001; Figure 2B).
Association of high CXCR4 expression with poor survival
outcome
In the univariate analysis, LN metastasis, poorly differentiated
tumour and CXCR4 expression predicted poor survival and
shorter DFS (Table 4). Patients with high CXCR4 tumour
expression clearly had a worse outcome than those with low
CXCR4 expression (OS: 9.7 months (95% CI: 6.0–13.4) vs 43.2
months (95% CI: 16.3–78.1), P¼0.0006; DFS: 8.6 months (95% CI:
5.8–11.3) vs 12.4 months (95% CI: 10.7–14.0, P¼0.067; Figure 3).
Patients with LN metastasis (OS: 12.6 (95% CI: 5.8–19.3) vs 43.3
months (95% CI, 3.3–75.8), P¼0.008; DFS 10.1 (95% CI: 8.0–12.1)
vs 22.6 months (95% CI: 4.0–83.9), P¼0.003) and poorly
differentiated tumour (OS: 18.6 (95% CI: 8.3–28.9) vs 8.8 months
(95% CI: 5.4–12.2), P¼0.03 and DFS: 12.1 (95% CI: 6.0–18.7) vs
6.3 months (95% CI: 3.0–9.5), P¼0.002) were also associated with
short DFS and OS.
In multivariate analysis (Table 5), CXCR4 expression, poorly
differentiated tumour and LN metastasis were negative inde-
pendent prognostic factors for OS whereas LN metastasis and
poorly differentiated tumour were negative prognostic indicators
for DFS.
CXCR4 and CXCR7 coexpression and patients outcome
Interestingly, patients with CXCR4
high/CXCR7
high tumour expres-
sion have a significantly prolonged DFS and OS than those patients
with a CXCR4
low/CXCR7
low tumour expression (Figure 3C; median
DFS: 15.80 months (95% CI: 10.43–21.17) vs 7.62 (2.97–12.27),
P¼0.037; median OS: not reached vs 9.69 (95% CI: 5.13–14.07),
P¼0.001).
Table 3 Correlation between CXCR4 expression and clinicopathologic
factors in pancreatic adenocarcinoma
CXCR4 expression
Variables Low n¼32 (%) High n¼39 (%) P-value
Age, mean ±s.d. 61.3±10.8 64.4±10.4 0.71
Gender
Male 16 (50) 23 (59.0)
Female 16 (50) 16 (41.0) 0.48
Tumour size
T1–T2 4 (12.5) 6 (15.4)
T3–T4 28 (87.5) 33 (84.6) 1.00
Tumour differentiation
Well/moderate 24 (87.5) 32 (82.1)
Poor 8 (12.5) 7 (17.9) 0.56
Lymph node
N0 16 (50.0) 7 (17.9)
N+ 16 (50.0) 32 (82.1) 0.015
Liver metastasis
a
Present 9 (28.1) 23 (59.0)
Absent 23 (71.9) 16 (41.0) 0.016
Vascular embols
Present 9 (28.1) 9 (76.9)
Absent 23 (71.9) 30 (23.1) 0.78
Lymphatic embols
Present 14 (43.8) 25 (64.1)
Absent 18 (56.2) 14 (35.9) 0.09
PI, mean±s.d. 18.5±9.86 26.6±9.39 0.001
PI¼proliferative index.
aRecurrence during follow-up.
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sDISCUSSION
In this study, we used immunohistochemical methods applied
to TMA technology to evaluate CXCR4, CXCR7 and HIF-1a
expressions in PA tissues and their impact on patients’ outcome.
The CXCR4 staining was predominantly cytoplasmic, whereas
a few cases presented an additional nuclear and/or membranous
localisation. A similar pattern has been recently described
(Maeda et al, 2008) and is explained by the translocation of
CXCR4 from the membrane to the cytoplasm (Burger et al, 2003).
CXCR4, CXCR7 and HIF-1a proteins expressions were
homogeneous within the different intratumour areas and no
difference of expression was detected between the primary and
LN metastasis. Positive correlations among the CXCR4, CXCR7
and HIF-1a expressions were found suggesting a possible role of
HIF-1a in the transcription activation of CXCR4 and CXCR7.
Hypoxia and HIF-1a is known to induce the transcription
of CXCR4 (Staller et al, 2003) and other chemoreceptors
including CCR7, CXCR1 and CXCR2 (Wilson et al, 2006;
Maxwell et al, 2007). It is credible that CXCR7 can be one of
the multiple genes targeted by HIF-1a suggesting that hypoxia can
trigger chemokines expression and enhance malignancy of tumour
cells in hypoxic area.
Data from in vitro and murine in vivo tumour models underline
the critical role of CXCR4/CXCL12 receptor ligand system for
pancreatic tumour cells. The CXCR4/CXCL12 system operates
probably as a paracrine loop (Mori et al, 2004) to enhance the
malignancy of pancreatic cancer cells. This enhanced malignancy
was generally attributed to a role of CXCR4 in cells migration,
matrix degradation and tissue invasion, as the ligand CXCL12 is
present in many tissues and thought to promote migration into
these tissues (Koshiba et al, 2000; Marchesi et al, 2004; Mori et al,
2004; Saur et al, 2005). Potential relationship among CXCR4,
CXCR7 expressions and cell proliferation was explored. There was
a significant positive correlation between the EI score of CXCR4
and PI. These observations are consistent with the fact that CXCR4
can also promote survival and proliferation of pancreatic
carcinoma cells (Koshiba et al, 2000; Marchesi et al, 2004; Saur
et al, 2005; Meijer et al, 2008). In contrast, CXCR7 EI score was not
correlated with PI. In vitro, CXCR7 activation induces proliferation
in pancreatic, colorectal, lung and mammary carcinoma cells (Miao
et al, 2007; Meijer et al, 2008). Surprisingly, despite the strong
Table 4 Overall survival and disease-free survival: univariate analysis
DFS OS
Variables OR (95% CI) P value OR (95% CI) P value
Age — 0.25 — 0.34
ECOG PS (0 vs 1) — 0.31 — 0.42
Sex — 0.53 — 0.56
Poorly differentiated tumour 2.17 (1.04–4.61) 0.04 2.32 (1.12–4.81) 0.031
T1,T2 vs T3,T4 — 0.33 — 0.20
Lymph node metastasis 2.94 (1.44–6.13) 0.003 2.16 (1.11–4.18) 0.02
Adjuvant treatment — 0.35 — 0.21
CXCR7
T Low (n¼29)
a 00
CXCR7
T high (n¼42) 1.51 (0.80–2.87) 0.20 1.81 (0.91–3.60) 0.12
CXCR4
Tl o w(n¼32)
a 11
CXCR4
T high (n¼39) 2.12 (0.98–3.82) 0.067 5.55 (1.92–12.31) 0.0006
HIF-1a
Tl o w(n¼26)
a 11
HIF-1a
T high (n¼35) 1.11 (0.61–2.02) 0.72 1.54 (0.82–2.94) 0.18
DFS¼disease-free survival; OS¼overall survival; ECOG PS¼Eastern Cooperative Oncology Group performance status; CXCR7
T¼CXCR7 expression in the tumour;
CXCR4
T¼CXCR4 expression in the tumour; HIF-1a¼hypoxia-inducible factor-1a; HIF-1a
T¼HIF-1a expression in the tumour.
aThe analysis of EI score as a continuous
variable did not modify the statistical results.
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Figure 2 (A) Increasing proliferative index correlate significantly with
rising EI scores for CXCR4 expression in pancreatic cancer (Po0.001).
(B) Proliferative index according to CXCR4 and CXCR7 expressions:
0¼CXCR4
low/CXCR7
low,1 ¼CXCR4
high/CXCR7
Low,2 ¼CXCR4
high/
CXCR7
high.
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sin vitro effects, CXCR7 did not influence colorectal tumour growth
in vivo, at least in a mouse xenograft model (Meijer et al, 2008),
whereas CXCR7 RNAi significantly reduced the tumour growth
of lung and mammary carcinomas (Miao et al, 2007). These
observations suggest that the influence of CXCR7 on tumours
growth is not generally applicable to carcinomas and indicate
potential inconsistency between in vitro and in vivo results.
In our study, CXCR4 tumour overexpression was associated with a
higher risk of LN metastasis, liver recurrence and was found to
be an independent negative prognosis factor for OS but not for
DFS. Although the rate of global recurrence was similar between
CXCR4
high and CXCR4
low tumours, occurrence of liver metastasis,
was significantly more frequent in CXCR4
high than CXCR4
low; this
can explain why CXCR4 expression failed to strongly predict DFS
whereas it appears to be a very good predictor for OS. CXCL12,
which is produced in a high level in the LN and the liver can initiate
and facilitate the homing of pancreatic cancer cells in these tissues
(Raman et al, 2007). Our results corroborate with a relevant
influence of CXCR4 on proliferation and haematogenous dissemina-
tion of PA in vivo and strengthen murine in vivo studies (Koshiba
et al, 2000; Marchesi et al, 2004; Kaifi et al,2 0 0 5 ;S a u ret al, 2005).
Recently, a study of Maeda et al investigating CXCR4 expression
in a PA patient population did not report a significant difference in
the 5-year survival rate between the patients with positive and
those with negative CXCR4 tumour expression (Maeda et al, 2008).
However, the prognostic value analysis of CXCR4 was restricted to
a specific CD133-positive subgroup of PA and not to the whole
population. Furthermore, Maeda et al also included patients with
R1 resection; these conditions can explain the survival difference
we presently have observed.
In our series, CXCR7 overexpression was not found as an
independent prognostic factor for DFS or OS. Many reasons could
explain these differences between CXCR4 and CXCR7 in predicting
survival despite the fact that they both bind CXCL12. Unlike
CXCR4, CXCL12 activation of CXCR7 does not induce calcium
mobilisation and cell migration (Burns et al, 2006) but rather
results in a proliferative effect and increased adhesion properties
(Miao et al, 2007; Sierro et al, 2007; Wang et al, 2008).
Furthermore, CXCR4 and CXCR7 have different CXCL12 binding
domains (Dambly-Chaudiere et al, 2007) and distinct roles during
development (Sierro et al, 2007). Although the CXCL12/CXCR4
and CXCL12/CXCR7 axes are important factors in cancer cell
Table 5 Disease free survival and overall survival: multivariate analysis
Variables Odds ratio 95% CI P value
Disease-free survival: Cox regression model
Lymph node metastasis
Absent 1
Present 3.03 1.49–6.17 0.002
Tumour differentiation
Well/moderate 1
Poor 2.40 1.14–5.05 0.021
CXCR4
a EI score
Low 1
High 1.86 0.99–3.49 0.054
Overall survival: Cox regression model
Lymph node metastasis
Absent 1
Present 2.88 1.34–6.21 0.007
Tumour differentiation
Well/moderate 1
Poor 2.24 0.95–5.49 0.11
CXCR4 EI score
a
Low 1
High 2.54 1.27–5.10 o0.001
CI¼Confident interval.
aThe analysis of the CXCR4 EI score as a continuous variable
did not modify results of the multivariate analysis.
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Figure 3 Kaplan–Meier analysis of survival (A) and DFS (B) according to CXCR4 expression. (C) OS according to subgroup combining analysis.
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ssurvival, differences exist between their roles in cancer, and
whether they function independently or synergistically should be
determined.
Interestingly, combining analysis of CXCR4 and CXCR7
coexpression allowed us to identify a subgroup of PA patients
(CXCR4
low/CXCR7
low) with a remarkably good prognosis.
Our results indicate that CXCR4 and CXCR7 could be attractive
targets for PA therapy. Small molecule CXCR4 antagonists are
currently being tested in phase I/II clinical trials and could be
attractive therapeutic candidates to combine with gemcitabine in
future clinical trials.
In conclusion, CXCR4 immunostaining of pancreatic cancer can
serve as a prognostic marker for survival after curative surgery. If
confirmed in larger prospective series, this assay may assist the
clinicians to select those patients who require adjuvant treatment
and may represent an attractive target for adjuvant therapy.
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